Icecure Medical (ICCM) has released an update.
IceCure Medical’s ProSense system showcased impressive results at the European Society of Breast Imaging Conference, with studies demonstrating its efficacy in cryoablation of breast tumors. Key highlights include the ICE3 trial’s 96.3% recurrence-free rate, the THERMAC trial’s 94% complete ablation rate, and the system’s approval in Europe for treating fibroadenomas and breast cancer. These findings underscore ProSense as a safe and effective minimally invasive treatment alternative to surgical tumor removal.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
